Contrasting United Therapeutics Corporation (UTHR) & Its Rivals
United Therapeutics Corporation (NASDAQ: UTHR) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare United Therapeutics Corporation to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
This table compares United Therapeutics Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|United Therapeutics Corporation||24.18%||20.96%||16.03%|
|United Therapeutics Corporation Competitors||-4,011.43%||-118.67%||-44.00%|
Volatility and Risk
United Therapeutics Corporation has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, United Therapeutics Corporation’s rivals have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.
This is a breakdown of current recommendations for United Therapeutics Corporation and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|United Therapeutics Corporation||3||6||2||0||1.91|
|United Therapeutics Corporation Competitors||797||2965||6485||146||2.58|
United Therapeutics Corporation currently has a consensus target price of $134.70, suggesting a potential upside of 9.67%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 4.05%. Given United Therapeutics Corporation’s higher possible upside, analysts plainly believe United Therapeutics Corporation is more favorable than its rivals.
Insider and Institutional Ownership
48.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 7.8% of United Therapeutics Corporation shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares United Therapeutics Corporation and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|United Therapeutics Corporation||$1.63 billion||$1.01 billion||14.33|
|United Therapeutics Corporation Competitors||$207.80 million||-$2.20 million||-0.21|
United Therapeutics Corporation has higher revenue and earnings than its rivals. United Therapeutics Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
United Therapeutics Corporation beats its rivals on 7 of the 13 factors compared.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.